Eisai sales on cancer-related drugs exceeds 100 billion Yen in FY2012

The most important product is eribulin (Halaven), a fully synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B. Aricept, another antitumor compound of Eisai, lost patent protection last year and shows reduction in sales.

Eisai press release, May 13, 2013

Eisai sales on cancer-related drugs exceeds 100 billion Yen in FY2012
Scroll to top